Table 2 Best response as assessed by the Independent Response Adjudication Committee (IRAC)
|  | Efficacy-evaluable population (n = 187) |
|---|---|
Overall response (CR + VGPR + PR), n (%) [95% CI] | 89 (47.6) [40.4–54.8] |
  CR, n (%) | 7 (3.7) |
  PR, n (%) | 82 (43.9) |
   VGPR, n (%) | 23 (12.3) |
Stable disease, n (%) | 88 (47.1) |
Progressive disease, n (%) | 10 (5.3) |
Median duration of response, months (range) | 8.8 (0.4–18.8) |
Median time to response, months (range) | 1.9 (0.9–10.2) |